% i/ W) y& i8 t5 f1 @+ E临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究:1 r/ q. k8 n0 d( W8 l
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.1 P+ ]# D8 G2 ]4 Y http://www.ncbi.nlm.nih.gov/pubmed/22968184) m$ v$ U8 E; c